Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)

Table 3

Adverse events resulting in dose reduction (DR) or discontinuation (DC) of therapy.

Adverse events	N	Grade	Attribution		Intervention
			Everolimus	Bevacizumab	Everolimus	Bevacizumab
Abdomen hemorrhage	1	5	−	+	DC	DC
Alanine aminotransferase	1	3	+	−	DC	DC
Proteinuria	1	2	−	+	DC	DC
Proteinuria	1	1	−	+	DC	DC
Neurologic decline	1	3	−	−	DC	DC
Back pain	1	2	−	−	DC	DC
Pain	1	4	−	−	DC	DC
Thromboembolism	1	3	−	−	None	DC
Fatigue	1	3	+	+	DR	None
Mucositis	2	2	+	−	DR	None
Mucositis	1	1	+	−	DR	None
Ear pain	1	1	+	−	DR	None

Off-treatment reason for these patients was disease progression.